WAT Stock Recent News
WAT LATEST HEADLINES
Waters Corporation (NYSE:WAT ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Amol Chaubal - Senior VP & CFO Caspar Tudor - Head of Investor Relations Udit Batra - President, CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Puneet Souda - Leerink Partners LLC, Research Division Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division Sung Ji Nam - Scotiabank Global Banking and Markets, Research Division Tycho W.
Waters (WAT) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $2.63 per share a year ago.
Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth In constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expected Raising full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and raising full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05 Second Quarter 2025 MILFORD, Mass. , Aug. 4, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the second quarter of 2025.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Waters Corporation (NYSE: WAT ) related to its merger with BD and Company's Biosciences and Diagnostic Solutions. Upon completion of the proposed transaction, existing Waters shareholders are expected to own approximately 60.8% of the combined company. Is it a fair deal?
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostic Solutions business. Upon completion of the proposed transaction, existing Waters shareholders are expected to own approximately 60.8% of the combined company. KSF is seeking to determin.
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.